Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMTX NASDAQ:KALV NASDAQ:MLTX NASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMTXImmatics$9.35+1.3%$10.30$5.05▼$12.41$1.25B1.32460,135 shs194,611 shsKALVKalVista Pharmaceuticals$27.00$26.90$9.83▼$27.00$1.44B-0.123.07 million shsN/AMLTXMoonLake Immunotherapeutics$19.52-4.4%$18.68$5.95▼$62.75$1.44B1.041.54 million shs1.09 million shsPALIPalisade Bio$1.93+2.1%$1.92$0.53▼$2.86$335.01M1.54.11 million shs3.33 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMTXImmatics-4.65%-7.61%-1.60%-15.71%+54.61%KALVKalVista Pharmaceuticals0.00%0.00%0.00%+33.07%+85.95%MLTXMoonLake Immunotherapeutics+0.25%+8.10%+9.20%+8.68%-58.35%PALIPalisade Bio-3.57%-7.35%+10.53%-8.25%+151.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMTXImmatics$9.35+1.3%$10.30$5.05▼$12.41$1.25B1.32460,135 shs194,611 shsKALVKalVista Pharmaceuticals$27.00$26.90$9.83▼$27.00$1.44B-0.123.07 million shsN/AMLTXMoonLake Immunotherapeutics$19.52-4.4%$18.68$5.95▼$62.75$1.44B1.041.54 million shs1.09 million shsPALIPalisade Bio$1.93+2.1%$1.92$0.53▼$2.86$335.01M1.54.11 million shs3.33 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMTXImmatics-4.65%-7.61%-1.60%-15.71%+54.61%KALVKalVista Pharmaceuticals0.00%0.00%0.00%+33.07%+85.95%MLTXMoonLake Immunotherapeutics+0.25%+8.10%+9.20%+8.68%-58.35%PALIPalisade Bio-3.57%-7.35%+10.53%-8.25%+151.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMTXImmatics 2.63Moderate Buy$20.80122.46% UpsideKALVKalVista Pharmaceuticals 2.22Hold$33.2523.15% UpsideMLTXMoonLake Immunotherapeutics 2.41Hold$24.2124.05% UpsidePALIPalisade Bio 3.00Buy$8.83357.69% UpsideCurrent Analyst Ratings BreakdownLatest PALI, KALV, MLTX, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026MLTXMoonLake Immunotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $29.006/30/2026PALIPalisade Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$7.006/30/2026PALIPalisade Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/29/2026PALIPalisade Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026PALIPalisade Bio LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/23/2026IMTXImmatics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/9/2026IMTXImmatics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/9/2026PALIPalisade Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/19/2026IMTXImmatics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMTXImmatics$54.60M22.96N/AN/A$4.09 per share2.29KALVKalVista Pharmaceuticals$1.43M1,008.07N/AN/A$2.71 per share9.96MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/APALIPalisade Bio$250K1,340.04N/AN/A$0.87 per share2.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMTXImmatics-$222.26M-$1.99N/AN/AN/A-572.35%-47.36%-39.35%8/12/2026 (Estimated)KALVKalVista Pharmaceuticals-$109.52M-$3.46N/A36.00N/AN/A-341.44%-111.94%8/13/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)PALIPalisade Bio-$16.78M-$1.01N/AN/AN/AN/A-36.79%-34.34%8/10/2026 (Estimated)Latest PALI, KALV, MLTX, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026PALIPalisade Bio-$0.05N/AN/AN/AN/AN/A8/4/2026Q2 2026MLTXMoonLake Immunotherapeutics-$0.91N/AN/AN/AN/AN/A5/14/2026Q1 2026KALVKalVista Pharmaceuticals-$0.3763-$0.43-$0.0538-$0.43$39.03 million$40.86 million5/12/2026Q1 2026IMTXImmatics-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million5/12/2026Q1 2026PALIPalisade Bio-$0.04-$0.05-$0.01-$0.05N/AN/A5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMTXImmaticsN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMTXImmaticsN/A8.788.78KALVKalVista Pharmaceuticals8.185.175.10MLTXMoonLake Immunotherapeutics0.398.608.60PALIPalisade BioN/A23.7123.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMTXImmatics64.41%KALVKalVista PharmaceuticalsN/AMLTXMoonLake Immunotherapeutics93.85%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipIMTXImmaticsN/AKALVKalVista Pharmaceuticals4.30%MLTXMoonLake Immunotherapeutics12.05%PALIPalisade Bio0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMTXImmatics260134.07 millionN/AOptionableKALVKalVista Pharmaceuticals10053.24 million50.95 millionOptionableMLTXMoonLake Immunotherapeutics273.61 million64.74 millionOptionablePALIPalisade Bio10173.58 million173.46 millionNot OptionablePALI, KALV, MLTX, and IMTX HeadlinesRecent News About These CompaniesPalisade Bio (NASDAQ:PALI) Downgraded to "Sell" Rating by Wall Street ZenJuly 13 at 1:06 AM | americanbankingnews.comWall Street Zen Downgrades Palisade Bio (NASDAQ:PALI) to SellJuly 13 at 1:05 AM | marketbeat.comRobert Jr. Baltera Purchases 25,000 Shares of Palisade Bio (NASDAQ:PALI) StockJuly 12 at 11:23 AM | americanbankingnews.comRobert Jr. Baltera Acquires 20,000 Shares of Palisade Bio (NASDAQ:PALI) StockJuly 11 at 10:21 AM | insidertrades.comInsider Buying: Palisade Bio (NASDAQ:PALI) Director Acquires $41,000.00 in StockJuly 11 at 9:27 AM | americanbankingnews.comInsider Buying: Palisade Bio (NASDAQ:PALI) Director Buys 20,000 SharesJuly 10, 2026 | marketbeat.comInsider Buying: Palisade Bio (NASDAQ:PALI) Director Acquires 25,000 SharesJuly 10, 2026 | marketbeat.comPalisade Bio to Participate in the Leerink Partners Therapeutics ForumJuly 10, 2026 | markets.businessinsider.comPalisade Bio to Participate in the Leerink Partners Therapeutics ForumJuly 10, 2026 | globenewswire.comPalisade Bio: A Unique MoA Targeting The UC And Crohn's Disease MarketsJuly 10, 2026 | seekingalpha.comInsider Buying: Palisade Bio (NASDAQ:PALI) Director Purchases 20,000 SharesJuly 9, 2026 | insidertrades.comPalisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Buys 20,000 SharesJuly 8, 2026 | marketbeat.comPalisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Acquires 30,000 Shares of StockJuly 8, 2026 | marketbeat.comPalisade Bio (NASDAQ:PALI) Insider Mitchell Lawrence Jones Sells 51,880 SharesJuly 8, 2026 | marketbeat.comPalisade Bio (NASDAQ:PALI) CEO John David Finley Sells 146,798 Shares of StockJuly 8, 2026 | marketbeat.comRobert Jr. Baltera Acquires 10,000 Shares of Palisade Bio (NASDAQ:PALI) StockJuly 7, 2026 | insidertrades.comPalisade Bio (NASDAQ:PALI) Director Acquires 20,000 SharesJuly 7, 2026 | americanbankingnews.comRobert Jr. Baltera Purchases 10,000 Shares of Palisade Bio (NASDAQ:PALI) StockJuly 7, 2026 | americanbankingnews.comPalisade Bio (NASDAQ:PALI) Upgraded by Wall Street Zen to "Hold" RatingJuly 5, 2026 | americanbankingnews.comPALI stock heads for best day in seven months – what’s driving today’s rally?June 29, 2026 | msn.comPalisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 TrialJune 29, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePALI, KALV, MLTX, and IMTX Company DescriptionsImmatics NASDAQ:IMTX$9.35 +0.12 (+1.30%) Closing price 04:00 PM EasternExtended Trading$9.36 +0.01 (+0.11%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.KalVista Pharmaceuticals NASDAQ:KALV$27.00 0.00 (0.00%) As of 06/12/2026KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.MoonLake Immunotherapeutics NASDAQ:MLTX$19.52 -0.89 (-4.36%) Closing price 04:00 PM EasternExtended Trading$19.82 +0.31 (+1.56%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Palisade Bio NASDAQ:PALI$1.93 +0.04 (+2.12%) Closing price 04:00 PM EasternExtended Trading$1.95 +0.02 (+1.24%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
